Why JanOne Shares Are Trading Higher Today
Why JanOne Shares Are Trading Higher Today
Janone股價今日為何走高
- JanOne Inc (NASDAQ:JAN) sold all of the assets, and none of the liabilities, of GeoTraq Inc., its wholly-owned subsidiary, to SPYR Inc (OTC:SPYR) for an aggregate of $13.5 million.
- The purchase price is payable in cash and shares of SPYR's common stock.
- SPYR issued 30 million shares of its common stock and delivered a five-year Promissory Note to JanOne in the initial principal amount of $12.6 million. The Promissory Note bears simple interest at an annual rate of 8% and delivers quarterly interest payments in arrears.
- "We believe this transaction further allows us to focus on our main business. Right now, our priority is the development of drugs with non-addictive, pain-relieving properties, specifically JAN101 (formerly known as TV1001SR), which is a potential treatment for peripheral artery disease (PAD). This sale of our subsidiary will help us continue to fund the necessary clinical trials for JAN101," commented Tony Isaac, CEO of JanOne.
- Price Action: JAN shares are trading higher by 83% at $4.10 and SPYR lower by 9.87% at $0.03 on the last check Tuesday.
- Janone Inc.(納斯達克股票代碼：JAN)將其全資子公司GeoTraq Inc.的所有資產，而不是任何負債出售給SPYR Inc.(場外交易：SPYR)，總計1350萬美元。
- 收購價格以現金和SPYR普通股的股票支付。
- SPYR發行了3000萬股普通股，並向Janone交付了一張五年期本票，初始本金為1260萬美元。本票的單息年利率為8%，每季度支付一次拖欠利息。
- Janone首席執行官託尼·艾薩克評論道：“我們相信，這筆交易將使我們進一步專注於我們的主業。目前，我們的首要任務是開發具有非成癮性、止痛性的藥物，特別是JAN101(以前稱為TV1001SR)，這是一種治療外周動脈疾病(PAD)的潛在藥物。此次出售我們的子公司將幫助我們繼續為JAN101提供必要的臨牀試驗資金。”
- 價格行動：在週二的最後一次檢查中，Jan的股價上漲了83%，至4.10美元，SPYR下跌了9.87%，至0.03美元。
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。